Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Kane Biotech's Average Total Inventories for the quarter that ended in Mar. 2026 was $0.36 Mil. Kane Biotech's Revenue for the
three
months ended in Mar. 2026 was $0.03 Mil.
Kane Biotech's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 11.52.
Kane Biotech's Inventory-to-Revenue for the quarter that ended in Mar. 2026
increased
from Dec. 2025 (0.00) to Dec. 2025 (11.52)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Kane Biotech's Days Inventory for the
three
months ended in Mar. 2026 was 958.13.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Kane Biotech's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.10.
Kane Biotech (OTCPK:KNBIF) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Kane Biotech's Days Inventory for the
three
months ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech Inventory-to-Revenue Related Terms
Kane Biotech Inventory-to-Revenue Historical Data
* Premium members only.
The historical data trend for Kane Biotech's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNBIF vs VRTX, REGN, RVMD: Inventory-to-Revenue Comparison
For the Biotechnology subindustry, Kane Biotech's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech Inventory-to-Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Kane Biotech's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Kane Biotech's Inventory-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech (KNBIF) has a Inventory-to-Revenue of 11.52 as of Mar. 2026. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Kane Biotech and its competitors.
Is Kane Biotech's Inventory-to-Revenue too high?
Kane Biotech's current Inventory-to-Revenue is 11.52.
How does Kane Biotech's Inventory-to-Revenue compare to VRTX and REGN?
Kane Biotech's Inventory-to-Revenue of 11.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory-to-Revenue for a Biotechnology company?
A good Inventory-to-Revenue depends on the Biotechnology industry context. However, Inventory-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory-to-Revenue mean?
A high Inventory-to-Revenue can signal that a stock is expensive relative to its fundamentals. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Kane Biotech and its competitors. Kane Biotech's current Inventory-to-Revenue is 11.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Inventory-to-Revenue of 11.52. The current Inventory-to-Revenue is 11.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory-to-Revenue calculated?
Inventory-to-Revenue is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Inventory-to-Revenue is 11.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 
